Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination

Jamie L. Morgan, Sangameshwar R. Baggari, Donald D. McIntire, Jeanne S. Sheffield

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective: To evaluate pregnancy outcomes of women who received tetanus, diphtheria, and acellular pertussis (Tdap) vaccination at or after 32 weeks of gestation. Outcomes from consecutive pregnancies during which the mother received Tdap were also analyzed. Methods: In a retrospective cohort study at a single institution, we compared pregnancy outcomes between those who accepted or declined Tdap at 32 weeks of gestation. Additionally, women who received Tdap vaccination in this and a prior pregnancy in the past 5 years were compared with multiparous women who only received Tdap in this pregnancy. Results: Since 2013, 7,378 women who were offered the Tdap vaccine antenatally delivered at our institution: 7,152 accepted (97%). There was no difference in stillbirths, major malformations, chorioamnionitis, 5-minute Apgar score, or cord blood pH. Neonatal complications including ventilation requirement, sepsis, intraventricular hemorrhage, and neonatal death were also similar. However, preterm birth rates at 36 weeks of gestation or less (6% compared with 12%, P<.001), incidence of small for gestational age (10% compared with 15%, P.03), and length of neonatal hospitalization (3.9 compared with 4.7 days, P<.001) were all significantly increased in the unvaccinated cohort. No difference in neonatal outcomes was noted between women who were administered at least two Tdap vaccines in the past 5 years (n1,229) and those who received only a single dose (n4,159). Conclusion: No adverse pregnancy outcomes were identified in association with antepartum Tdap vaccination. This remained true in women receiving more than one Tdap vaccine in a 5-year timeframe. This may be the result of a type II error.

Original languageEnglish (US)
Pages (from-to)1433-1438
Number of pages6
JournalObstetrics and Gynecology
Volume125
Issue number6
DOIs
StatePublished - Jun 28 2015

Fingerprint

Diphtheria
Whooping Cough
Tetanus
Pregnancy Outcome
Vaccination
Diphtheria-Tetanus-acellular Pertussis Vaccines
Pregnancy
Chorioamnionitis
Stillbirth
Apgar Score
Birth Rate
Premature Birth
Fetal Blood
Gestational Age
Ventilation
Sepsis
Hospitalization
Cohort Studies
Retrospective Studies
Mothers

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. / Morgan, Jamie L.; Baggari, Sangameshwar R.; McIntire, Donald D.; Sheffield, Jeanne S.

In: Obstetrics and Gynecology, Vol. 125, No. 6, 28.06.2015, p. 1433-1438.

Research output: Contribution to journalArticle

@article{658454b50f9e4efba95d2aa9530f4789,
title = "Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination",
abstract = "Objective: To evaluate pregnancy outcomes of women who received tetanus, diphtheria, and acellular pertussis (Tdap) vaccination at or after 32 weeks of gestation. Outcomes from consecutive pregnancies during which the mother received Tdap were also analyzed. Methods: In a retrospective cohort study at a single institution, we compared pregnancy outcomes between those who accepted or declined Tdap at 32 weeks of gestation. Additionally, women who received Tdap vaccination in this and a prior pregnancy in the past 5 years were compared with multiparous women who only received Tdap in this pregnancy. Results: Since 2013, 7,378 women who were offered the Tdap vaccine antenatally delivered at our institution: 7,152 accepted (97{\%}). There was no difference in stillbirths, major malformations, chorioamnionitis, 5-minute Apgar score, or cord blood pH. Neonatal complications including ventilation requirement, sepsis, intraventricular hemorrhage, and neonatal death were also similar. However, preterm birth rates at 36 weeks of gestation or less (6{\%} compared with 12{\%}, P<.001), incidence of small for gestational age (10{\%} compared with 15{\%}, P.03), and length of neonatal hospitalization (3.9 compared with 4.7 days, P<.001) were all significantly increased in the unvaccinated cohort. No difference in neonatal outcomes was noted between women who were administered at least two Tdap vaccines in the past 5 years (n1,229) and those who received only a single dose (n4,159). Conclusion: No adverse pregnancy outcomes were identified in association with antepartum Tdap vaccination. This remained true in women receiving more than one Tdap vaccine in a 5-year timeframe. This may be the result of a type II error.",
author = "Morgan, {Jamie L.} and Baggari, {Sangameshwar R.} and McIntire, {Donald D.} and Sheffield, {Jeanne S.}",
year = "2015",
month = "6",
day = "28",
doi = "10.1097/AOG.0000000000000862",
language = "English (US)",
volume = "125",
pages = "1433--1438",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination

AU - Morgan, Jamie L.

AU - Baggari, Sangameshwar R.

AU - McIntire, Donald D.

AU - Sheffield, Jeanne S.

PY - 2015/6/28

Y1 - 2015/6/28

N2 - Objective: To evaluate pregnancy outcomes of women who received tetanus, diphtheria, and acellular pertussis (Tdap) vaccination at or after 32 weeks of gestation. Outcomes from consecutive pregnancies during which the mother received Tdap were also analyzed. Methods: In a retrospective cohort study at a single institution, we compared pregnancy outcomes between those who accepted or declined Tdap at 32 weeks of gestation. Additionally, women who received Tdap vaccination in this and a prior pregnancy in the past 5 years were compared with multiparous women who only received Tdap in this pregnancy. Results: Since 2013, 7,378 women who were offered the Tdap vaccine antenatally delivered at our institution: 7,152 accepted (97%). There was no difference in stillbirths, major malformations, chorioamnionitis, 5-minute Apgar score, or cord blood pH. Neonatal complications including ventilation requirement, sepsis, intraventricular hemorrhage, and neonatal death were also similar. However, preterm birth rates at 36 weeks of gestation or less (6% compared with 12%, P<.001), incidence of small for gestational age (10% compared with 15%, P.03), and length of neonatal hospitalization (3.9 compared with 4.7 days, P<.001) were all significantly increased in the unvaccinated cohort. No difference in neonatal outcomes was noted between women who were administered at least two Tdap vaccines in the past 5 years (n1,229) and those who received only a single dose (n4,159). Conclusion: No adverse pregnancy outcomes were identified in association with antepartum Tdap vaccination. This remained true in women receiving more than one Tdap vaccine in a 5-year timeframe. This may be the result of a type II error.

AB - Objective: To evaluate pregnancy outcomes of women who received tetanus, diphtheria, and acellular pertussis (Tdap) vaccination at or after 32 weeks of gestation. Outcomes from consecutive pregnancies during which the mother received Tdap were also analyzed. Methods: In a retrospective cohort study at a single institution, we compared pregnancy outcomes between those who accepted or declined Tdap at 32 weeks of gestation. Additionally, women who received Tdap vaccination in this and a prior pregnancy in the past 5 years were compared with multiparous women who only received Tdap in this pregnancy. Results: Since 2013, 7,378 women who were offered the Tdap vaccine antenatally delivered at our institution: 7,152 accepted (97%). There was no difference in stillbirths, major malformations, chorioamnionitis, 5-minute Apgar score, or cord blood pH. Neonatal complications including ventilation requirement, sepsis, intraventricular hemorrhage, and neonatal death were also similar. However, preterm birth rates at 36 weeks of gestation or less (6% compared with 12%, P<.001), incidence of small for gestational age (10% compared with 15%, P.03), and length of neonatal hospitalization (3.9 compared with 4.7 days, P<.001) were all significantly increased in the unvaccinated cohort. No difference in neonatal outcomes was noted between women who were administered at least two Tdap vaccines in the past 5 years (n1,229) and those who received only a single dose (n4,159). Conclusion: No adverse pregnancy outcomes were identified in association with antepartum Tdap vaccination. This remained true in women receiving more than one Tdap vaccine in a 5-year timeframe. This may be the result of a type II error.

UR - http://www.scopus.com/inward/record.url?scp=84929862438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929862438&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000000862

DO - 10.1097/AOG.0000000000000862

M3 - Article

VL - 125

SP - 1433

EP - 1438

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -